Evidence method
Level · gp.fundamentals.debt_to_revenue
213.99% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RDNT · Jun 30, 2026
RadNet, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-26-055338General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
15.11% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
24.99% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
6.34% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.69% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History5 statesHistory building
Period transition
What moved in the state?
- Previous
- 188.75%
- Current
- 213.99%
- Delta
- 25.24%
- Previous
- 13.72%
- Current
- 15.11%
- Delta
- 1.39%
- Previous
- 22.11%
- Current
- 24.99%
- Delta
- 2.88%
- Previous
- -4.15%
- Current
- 6.34%
- Delta
- 10.49%
- Previous
- 5.45%
- Current
- 1.69%
- Delta
- -3.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Services-Medical Laboratories peers →Has State · RadNet, Inc. →Transitioned To · RDNT Fundamental State →Transitioned To · RDNT BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · RDNT CASH_GENERATION_INCREASED →Transitioned To · RDNT GROWTH_INCREASED →Transitioned To · RDNT PROFITABILITY_INCREASED →Transitioned To · RDNT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.